Can cord blood save your sight? new trial for dry AMD

NCT ID NCT06536062

Recruiting now Disease control Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tests whether injecting a special blood product from umbilical cords into the eye can slow vision loss in people with dry age-related macular degeneration (AMD). The trial will involve 36 participants aged 65 and older with bilateral dry AMD. One eye will receive the injection, and the other will get a sham procedure for comparison.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: umbilical cord blood platelet-rich plasma (CB-PRP) injection
What this could lead to: If it works, this could point toward a treatment that slows or stops vision loss in dry age-related macular degeneration.
What could go wrong: This is a small, early-phase trial with only 36 participants. The treatment involves an injection into the eye, which carries risks like infection or inflammation. Success is not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY AGE-RELATED MACULAR DEGENERATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry age related macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRY AGE-RELATED MACULAR DEGENERATION

Contacts and locations

Locations

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
RECRUITING

Rome, Rome, 00168, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.